Earnings

Abbvie Shared Detailed Results From The Multiple Ascending Dose Part Of Its Phase 1 Study Evaluating ABBV-295 At EASD Annual Meeting, Showing Favorable Tolerability And Pharmacokinetic Profile

Sep 30, 2026 · 05:57 AM ET· updated 1h ago

AbbVie (NYSE:ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association

Why It Matters

AbbVie showed that a new medicine called ABBV-295 works safely in early testing. When a medicine passes its first safety tests, it means the company is moving toward helping real patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV265.76

+2.46 (+0.94%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.